Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 4 institutions in 1 country.
Melissa V Fernandez-de CéspedesHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institutegrid.48336.3a, Frederick, Maryland, USA.ORCID 0000-0001-7506-7961
Huxley K HoffmanBiological Sciences, University of Denver, Denver, Colorado, USA.ORCID 0000-0002-4509-0594
Hannah CarterHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institutegrid.48336.3a, Frederick, Maryland, USA.ORCID 0000-0002-4758-1178
Lacy M SimonsDivision of Infectious Diseases, Center for Pathogen Genomics and Microbial Evolution, Havey Institute for Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-4041-6775
Lwar NaingHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institutegrid.48336.3a, Frederick, Maryland, USA.ORCID 0000-0002-0290-9256
Sherimay D AblanHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institutegrid.48336.3a, Frederick, Maryland, USA.ORCID 0000-0001-9466-8332
David A ScheiblinOptical Microscopy and Analysis Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID 0000-0002-5505-2540
Judd F HultquistDivision of Infectious Diseases, Center for Pathogen Genomics and Microbial Evolution, Havey Institute for Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-6424-4280
Schuyler B van EngelenburgBiological Sciences, University of Denver, Denver, Colorado, USA.ORCID 0000-0003-2100-3617
Eric O FreedHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institutegrid.48336.3a, Frederick, Maryland, USA.ORCID 0000-0003-3345-022X
National Cancer Institute · USNorthwestern University · USUniversity of Denver · USFrederick National Laboratory for Cancer Research · US
Funding
X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2007 to 2018
$48.8M
Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sahera Dirajlal-Fargo · 2015 to 2026
$38.4M
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDREJ SALI · 2022 to 2026
$35.7M
Functionally Defining HIV-Host Interactions During the Early HIV-1 LifecycleR01AI150998 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIENIASZ, PAUL D., HOPE, THOMAS · 2020 to 2024
$6.8M
Identifying determinants of HIV-1 responsible for the nanoscale distribution and dynamics of virus assemblyR01AI138625 · NIAID · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI Schuyler van Engelenburg · 2018 to 2026
$3.3M
Regulation of SAMHD1 antiviral activityR01AI150455 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DIAZ-GRIFFERO, FELIPE · 2019 to 2024
$3.3M
Deciphering the Role of CPSF6 in HIV InfectionR01AI165236 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2021 to 2025
The HIV-1 envelope glycoprotein (Env) contains a long cytoplasmic tail harboring highly conserved motifs that direct Env trafficking and incorporation into virions and promote efficient virus spread. The cellular trafficking factor Rab11a family interacting protein 1C (FIP1C) has been implicated in the directed trafficking of Env to sites of viral assembly. In this study, we confirm that small interfering RNA (siRNA)-mediated depletion of FIP1C in HeLa cells modestly reduces Env incorporation into virions. To determine whether FIP1C is required for Env incorporation and HIV-1 replication in physiologically relevant cells, CRISPR-Cas9 technology was used to knock out the expression of this protein in several human T-cell lines-Jurkat E6.1, SupT1, and H9-and in primary human CD4
Indexed as
Adaptor Proteins, Signal TransducingCD4-Positive T-LymphocytesHIV-1Membrane ProteinsVirus Replicationenv Gene Products, Human Immunodeficiency VirusHeLa CellsHIV Envelope Protein gp41HumansVirus AssemblyAdaptor Proteins, Signal Transducingenv Gene Products, Human Immunodeficiency VirusHIV Envelope Protein gp41Membrane ProteinsRAB11FIP1 protein, humancytoplasmic tailEnvFIP1Cgp41HIV-1incorporationprotein traffickingRab proteinsretrovirustraffickingtransmissionvirus assembly
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4 · full record | OpenQuestion